Efficacy O O O O
of O O O O
ChAdOx1 O O O O
nCoV-19 O O O O
Vaccine O O O O
Against O O O O
B.1.1.7 O O O O
Variant O O O O
Quick O O O O
Takes O O O O
- O O O O
The O O O O
B.1.1.7 O O O O
variant O O O O
of O O O O
SARS-CoV-2 O O O O
is O O O O
associated O O O O
with O O O O
higher O O O O
viral O O O O
loads O O O O
and O O O O
increased O O O O
risk O O O O
of O O O O
transmission O O O O
compared O O O O
to O O O O
non-B.1.1.7 O O O O
variants. O O O O
- O O O O
This O O O O
study O O O O
is O O O O
a O O O O
post O O O O
hoc O O O O
in O O O O
vitro O O O O
and O O O O
in O O O O
vivo O O O O
efficacy O O O O
analysis O O O O
of O O O O
the O O O O
Oxford/AstraZeneca O O O O
ChAdOx1 O O O O
vaccine O O O O
using O O O O
data O O O O
from O O O O
the O O O O
UK O O O O
COV002 O O O O
phase O O O O
2/3 O O O O
trial. O O O O
- O O O O
In O O O O
vitro O O O O
neutralization O O O O
activity O O O O
against O O O O
the O O O O
B.1.1.7 O O O O
variant O O O O
using O O O O
sera O O O O
from O O O O
vaccinated O O O O
participants O O O O
appeared O O O O
to O O O O
be O O O O
reduced O O O O
compared O O O O
to O O O O
non-B.1.1.7 O O O O
variants, O O O O
but O O O O
clinical O O O O
efficacy O O O O
of O O O O
the O O O O
ChAdOx1 O O O O
was O O O O
similar O O O O
in O O O O
preventing O O O O
symptomatic O O O O
COVID-19 O O O O
due O O O O
to O O O O
both O O O O
variants. O O O O
Study Reason 3 O O
Questions: Reason 3 O O
Is Reason 3 O O
the Reason 3 O O
Oxford/AstraZeneca Reason 3 O O
ChAdOx1 Reason 3 O O
vaccine Reason 3 O O
effective Reason 3 O O
against Reason 3 O O
the Reason 3 O O
severe Reason 3 O O
acute Reason 3 O O
respiratory Reason 3 O O
syndrome Reason 3 O O
coronavirus Reason 3 O O
2 Reason 3 O O
(SARS-CoV-2) Reason 3 O O
B.1.1.7 Reason 3 O O
variant? Reason 3 O O
Methods: Reason 3 O O
This Reason 3 O O
study Reason 3 O O
reports Reason 3 O O
the Reason 3 O O
results Reason 3 O O
of Reason 3 O O
an Reason 3 O O
in Reason 3 O O
vitro Reason 3 O O
analysis Reason 3 O O
of Reason 3 O O
vaccine-induced Reason 3 O O
neutralizing Reason 3 O O
antibody Reason 3 O O
responses Reason 3 O O
against Reason 3 O O
B.1.1.7, Reason 3 O O
and Reason 3 O O
a Reason 3 O O
post Reason 3 O O
hoc Reason 3 O O
analysis Reason 3 O O
of Reason 3 O O
the Reason 3 O O
clinical Reason 3 O O
efficacy Reason 3 O O
of Reason 3 O O
ChAdOx1 Reason 3 O O
nCoV-19 Reason 3 O O
against Reason 3 O O
disease Reason 3 O O
caused Reason 3 O O
by Reason 3 O O
the Reason 3 O O
B.1.1.7 Reason 3 O O
variant Reason 3 O O
of Reason 3 O O
concern, Reason 3 O O
using Reason 3 O O
data Reason 3 O O
from Reason 3 O O
the Reason 3 O O
UK Reason 3 O O
COV002 Reason 3 O O
phase Reason 3 O O
2/3 Reason 3 O O
trial Reason 3 O O
assessing Reason 3 O O
the Reason 3 O O
safety Reason 3 O O
and Reason 3 O O
efficacy Reason 3 O O
of Reason 3 O O
the Reason 3 O O
ChAdOx1 Reason 3 O O
nCoV-19 Reason 3 O O
vaccine. Reason 3 O O
Adults O O O O
enrolled O O O O
in O O O O
the O O O O
trial O O O O
(n O O O O
= O O O O
8,534) O O O O
provided O O O O
weekly O O O O
self-collected O O O O
nose O O O O
and O O O O
throat O O O O
swabs O O O O
for O O O O
SARS-CoV-2 O O O O
nucleic O O O O
acid O O O O
testing O O O O
and O O O O
subsequent O O O O
sequencing. O O O O
Immunogenicity O O O O
was O O O O
tested O O O O
in O O O O
vitro O O O O
using O O O O
sera O O O O
from O O O O
vaccinated O O O O
participants O O O O
and O O O O
the O O O O
B.1.1.7 O O O O
lineage O O O O
and O O O O
a O O O O
canonical O O O O
non-B.1.1.7 O O O O
viral O O O O
lineages O O O O
(BetaCoV/Australia/VIC01/2020). O O O O
The O O O O
primary O O O O
outcome O O O O
was O O O O
symptomatic O O O O
coronavirus O O O O
disease O O O O
2019 O O O O
(COVID-19) O O O O
disease, O O O O
defined O O O O
as O O O O
a O O O O
positive O O O O
nuclear O O O O
acid O O O O
test O O O O
result O O O O
on O O O O
an O O O O
upper O O O O
airway O O O O
swab O O O O
in O O O O
a O O O O
participant O O O O
with O O O O
at O O O O
least O O O O
one O O O O
symptom. O O O O
Results: O O O O
Of O O O O
8,534 O O O O
participants O O O O
in O O O O
the O O O O
primary O O O O
efficacy O O O O
cohort, O O O O
6,636 O O O O
(78%) O O O O
were O O O O
aged O O O O
18-55 O O O O
years O O O O
and O O O O
5,065 O O O O
(59%) O O O O
were O O O O
female. O O O O
Between O O O O
October O O O O
1, O O O O
2020, O O O O
and O O O O
January O O O O
14, O O O O
2021, O O O O
520 O O O O
participants O O O O
developed O O O O
SARS-CoV-2 O O O O
infection. O O O O
1,466 O O O O
nucleic O O O O
acid O O O O
amplification O O O O
test O O O O
(NAAT)-positive O O O O
nose O O O O
and O O O O
throat O O O O
swabs O O O O
were O O O O
collected O O O O
from O O O O
these O O O O
participants O O O O
during O O O O
the O O O O
trial. O O O O
Of O O O O
these, O O O O
401 O O O O
swabs O O O O
from O O O O
311 O O O O
participants O O O O
were O O O O
successfully O O O O
sequenced. O O O O
Among O O O O
symptomatic O O O O
cases, O O O O
52 O O O O
(35%) O O O O
of O O O O
147 O O O O
were O O O O
due O O O O
to O O O O
the O O O O
B.1.1.7 O O O O
variant O O O O
and O O O O
95 O O O O
(65%) O O O O
were O O O O
caused O O O O
by O O O O
non-B.1.1.7 O O O O
lineages. O O O O
Laboratory O O O O
virus O O O O
neutralization O O O O
activity O O O O
by O O O O
vaccine-induced O O O O
antibodies O O O O
was O O O O
lower O O O O
against O O O O
the O O O O
B.1.1.7 O O O O
variant O O O O
than O O O O
against O O O O
non-B.1.1.7 O O O O
lineage O O O O
(geometric O O O O
mean O O O O
ratio, O O O O
8.9; O O O O
95% O O O O
confidence O O O O
interval O O O O
[CI], O O O O
7.2-11.0). O O O O
Clinical O O O O
vaccine O O O O
efficacy O O O O
against O O O O
NAAT-positive O O O O
infection O O O O
CI, O O O O
(95% O O O O
CI, O O O O
67.9-89.4) O O O O
for O O O O
non-B.1.1.7 O O O O
lineages. O O O O
None O O O O
of O O O O
the O O O O
participants O O O O
were O O O O
hospitalized O O O O
or O O O O
died O O O O
due O O O O
to O O O O
COVID-19. O O O O
Conclusions: Reason 5 O O
In Reason 5 O O
vitro Reason 5 O O
ChAdOx1 Reason 5 O O
nCoV-19 Reason 5 O O
showed Reason 5 O O
reduced Reason 5 O O
neutralization Reason 5 O O
activity Reason 5 O O
against Reason 5 O O
the Reason 5 O O
B.1.1.7 Reason 5 O O
variant Reason 5 O O
compared Reason 5 O O
with Reason 5 O O
a Reason 5 O O
non-B.1.1.7 Reason 5 O O
variant; Reason 5 O O
however, Reason 5 O O
clinical Reason 5 O O
efficacy Reason 5 O O
of Reason 5 O O
the Reason 5 O O
vaccine Reason 5 O O
was Reason 5 O O
similar Reason 5 O O
against Reason 5 O O
the Reason 5 O O
B.1.1.7 Reason 5 O O
and Reason 5 O O
non-B.1.1.7 Reason 5 O O
variants Reason 5 O O
of Reason 5 O O
SARS-CoV-2. Reason 5 O O
Perspective: Reason 5 O O
This Reason 5 O O
study Reason 5 O O
adds Reason 5 O O
to Reason 5 O O
the Reason 5 O O
mounting Reason 5 O O
evidence Reason 5 O O
of Reason 5 O O
vaccine Reason 5 O O
effectiveness Reason 5 O O
against Reason 5 O O
the Reason 5 O O
different Reason 5 O O
variants Reason 5 O O
of Reason 5 O O
SARS-CoV-2. Reason 5 O O
The O O O O
B.1.1.7 O O O O
SARS-CoV-2 O O O O
variant O O O O
first O O O O
identified O O O O
in O O O O
the O O O O
UK O O O O
in O O O O
late O O O O
2020 O O O O
has O O O O
23 O O O O
mutations O O O O
across O O O O
the O O O O
viral O O O O
genome; O O O O
significantly O O O O
more O O O O
than O O O O
other O O O O
lineages. O O O O
Some O O O O
of O O O O
these O O O O
mutations O O O O
of O O O O
the O O O O
spike O O O O
protein O O O O
coding O O O O
region O O O O
have O O O O
been O O O O
shown O O O O
to O O O O
increase O O O O
ACE2 O O O O
receptor O O O O
binding O O O O
affinity O O O O
and O O O O
viral O O O O
escape O O O O
in O O O O
immunocompromised O O O O
individuals. O O O O
At Reason 5 O O
the Reason 5 O O
time Reason 5 O O
the Reason 5 O O
B.1.1.7 Reason 5 O O
was Reason 5 O O
identified, Reason 5 O O
population Reason 5 O O
immunity Reason 5 O O
to Reason 5 O O
the Reason 5 O O
natural Reason 5 O O
infection Reason 5 O O
was Reason 5 O O
low, Reason 5 O O
and Reason 5 O O
vaccine Reason 5 O O
programs Reason 5 O O
had Reason 5 O O
not Reason 5 O O
been Reason 5 O O
initiated. Reason 5 O O
Thus, Reason 5 O O
the Reason 5 O O
rapid Reason 5 O O
spread Reason 5 O O
of Reason 5 O O
the Reason 5 O O
variant Reason 5 O O
is Reason 5 O O
likely Reason 5 O O
due Reason 5 O O
to Reason 5 O O
its Reason 5 O O
improved Reason 5 O O
affinity Reason 5 O O
to Reason 5 O O
the Reason 5 O O
ACE2 Reason 5 O O
receptor Reason 5 O O
rather Reason 5 O O
than Reason 5 O O
the Reason 5 O O
result Reason 5 O O
of Reason 5 O O
vaccine-induced Reason 5 O O
immunity, Reason 5 O O
and Reason 5 O O
does Reason 5 O O
not Reason 5 O O
represent Reason 5 O O
a Reason 5 O O
"resistant" Reason 5 O O
strain. Reason 5 O O
Neutralizing Reason 5 O O
antibodies Reason 5 O O
to Reason 5 O O
SARS-CoV-2 Reason 5 O O
may Reason 5 O O
target Reason 5 O O
various Reason 5 O O
epitopes Reason 5 O O
in Reason 5 O O
different Reason 5 O O
areas Reason 5 O O
of Reason 5 O O
the Reason 5 O O
spike Reason 5 O O
protein Reason 5 O O
and Reason 5 O O
could Reason 5 O O
provide Reason 5 O O
protein Reason 5 O O
against Reason 5 O O
infection Reason 5 O O
even Reason 5 O O
in Reason 5 O O
the Reason 5 O O
presence Reason 5 O O
of Reason 5 O O
different Reason 5 O O
mutations. Reason 5 O O
The Reason 5 O O
fears Reason 5 O O
surrounding Reason 5 O O
the Reason 5 O O
spread Reason 5 O O
of Reason 5 O O
novel Reason 5 O O
SARS-CoV-2 Reason 5 O O
variants Reason 5 O O
and Reason 5 O O
their Reason 5 O O
resistance Reason 5 O O
to Reason 5 O O
current Reason 5 O O
vaccines Reason 5 O O
are Reason 5 O O
so Reason 5 O O
far Reason 5 O O
not Reason 5 O O
validated. Reason 5 O O
Vaccination Reason 5 O O
remains Reason 5 O O
the Reason 5 O O
only Reason 5 O O
viable Reason 5 O O
solution Reason 5 O O
to Reason 5 O O
end Reason 5 O O
this Reason 5 O O
pandemic. Reason 5 O O
Clinical O O O O
Topics: O O O O
[COVID-19 O O O O
Hub, O O O O
](/Clinical-Topics/COVID-19-Hub) O O O O
[Prevention](/Clinical-Topics/Prevention) O O O O
Keywords: O O O O
